DEFENCE THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.25 CAD | +2.46% |
|
-13.79% | -46.35% |
| Sales 2022 | - | Sales 2023 | - | Capitalization | 128M 174M 10.21B |
|---|---|---|---|---|---|
| Net income 2022 | -7M -9.57M -560M | Net income 2023 | -6M -8.2M -480M | EV / Sales 2022 | - |
| Net cash position 2022 | 507K 693K 40.56M | Net cash position 2023 | 1.05M 1.43M 83.8M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-9.83
x | P/E ratio 2023 |
-17.1
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 95.28% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +2.46% | ||
| 1 week | -13.79% | ||
| Current month | -26.90% | ||
| 1 month | -26.47% | ||
| 3 months | -39.02% | ||
| 6 months | -56.60% | ||
| Current year | -46.35% |
1 week
1.12
1.45
1 month
1.121.75
Current year
1.122.55
1 year
1.123.30
3 years
1.128.15
5 years
1.128.15
10 years
1.128.15
| Managers | Title | Age | Since |
|---|---|---|---|
Simon Beaudoin
FOU | Founder | 40 | 17/07/17 |
| Founder | 51 | 17/07/17 | |
P. Meagher
DFI | Director of Finance/CFO | 39 | 17/09/20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | 51 | 17/07/17 | |
P. Meagher
DFI | Director of Finance/CFO | 39 | 17/09/20 |
Raimar Löbenberg
CHM | Chairman | 58 | 04/01/21 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 1.25 | +2.46% | 58,500 |
| 25/04/24 | 1.22 | -0.81% | 9,600 |
| 24/04/24 | 1.23 | 0.00% | 23,000 |
| 23/04/24 | 1.23 | -3.91% | 41,860 |
| 22/04/24 | 1.28 | -11.72% | 24,410 |
Delayed Quote Canadian Securities Exchange, April 26, 2024 at 08:12 pm
More quotes
Defence Therapeutics Inc. is a Canada-based biotechnology company working on engineering vaccines and antibody drug conjugates (ADC) products using its proprietary platform. The Company is engaged in the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological-/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. Its platform's core is the Accum technology, which enables delivery of vaccine antigens or ADCs in their intact form to target cells. The Company is focused on research, development and advancement of various products using its Accum technology, which include Dendritic Cell cancer vaccines using Accum (Accuvac); a new protein-based vaccine formulation against COVID and infectious diseases; ADC targeting various cancers; anti-cancer AccuTOX program; cervical cancer vaccine; mesenchymal stromal cell-based vaccine (ARM) targeting cancer, and messenger ribonucleic acid vaccination.
Calendar
23/05/2024
- Q3 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -46.35% | 41.49M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- DTC Stock
